IP Library Granted Patent US 7,872,050
Granted Patent B2
US 7,872,050 · App. 11/369,305 · Granted Jan 18, 2011

Stabilized compositions of volatile alkylating agents and methods of using thereof

Assignee: Yaupon Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,872,050
App. No.
11/369,305
Granted
Jan 18, 2011
Kind
B2
Abstract

A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.

Claims (19)

1. A method for treating a person with a skin disorder, comprising:

topically applying to the affected skin a composition comprising:

an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient consists essentially of a pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine;

a vehicle or carrier that is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 1-6 carbon atoms; and

an organic acid in an amount of about 1 percent to about 15 percent by weight of the composition,

wherein the skin disorder is psoriasis, mycosis fungoides, or alopecia.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine is present in an amount of about 0.0001 to about 2.0 weight percent of the composition.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine is present in an amount of about 0.01 to about 0.04 weight percent of the composition.

4. The method of claim 1 , wherein the pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine is present in an amount of about 0.015 to about 0.030 weight percent of the composition.

5. The method of claim 1 , wherein the organic acid is oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 2-acetoxybenzoic acid, acetic acid, phenylacetic acid, propionic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, glutamic acid, salicylic acid, sulfanilic acid, or fumaric acid.

6. The method of claim 1 , wherein the organic acid is lactic acid.

7. The method of claim 1 , wherein the vehicle or carrier is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 2 carbon atoms (Ethoxy Diglycol Reagent).

8. The method of claim 1 , wherein the skin disorder is mycosis fungoides.

9. The method of claim 1 , wherein the skin disorder is psoriasis.

10. The method of claim 1 , wherein the skin disorder is alopecia.

11. The method of claim 1 , wherein the vehicle or carrier is a non-aqueous vehicle or carrier.

12. The method of claim 11 , wherein the non-aqueous vehicle or carrier is a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 2 carbon atoms (Ethoxy Diglycol Reagent).

13. The method of claim 7 , wherein the organic acid is lactic acid.

14. The method of claim 12 , wherein the organic acid is lactic acid.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2020
From: ACTELION PHARMACEUTICALS LTD
To: HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 051542/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CEPTARIS THERAPEUTICS, INC.
To: ACTELION PHARMACEUTICALS, LTD.
Reel/Frame 031896/0320 →
CHANGE OF NAME Recorded Feb 24, 2012
From: YAUPON THERAPEUTICS, INC.
To: CEPTARIS THERAPEUTICS, INC.
Reel/Frame 027757/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2007
From: AL-GHANANEEM, ABEER M., PHD
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 019748/0289 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2006
From: ALONSO, MR. ROBERT; CROOKS, PHD, MR. PETER A.; PIMLEY, MR. MARK A.; LESSIN, MD, MR. STUART R.
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 017399/0740 →
Continuity (3)
Provisional Application 6066135600 · Mar 14, 2005
Provisional Application 6075112800 · Dec 16, 2005
Related Publication 20060205694A1 · Sep 14, 2006